Clinical Analysis of 46 Cases of Multiple Myeloma with Extramedullary Disease / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 115-121, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-880041
ABSTRACT
OBJECTIVE@#To investigate the effect of clinical baseline data on prognosis in patients with multiple myeloma (MM) complicated by extramedullary disease (EMD).@*METHODS@#The clinical data of 46 MM patients with EMD were retrospectively analyzed. The clinical data and survival prognosis of MM patients in primary EMD group and recurrent EMD group were analyzed. The classified baseline data were expressed by the number of cases (percentage), the χ@*RESULTS@#β @*CONCLUSION@#The remission depth of primary EMD group≥VGPR is lower than that of recurrent EMD group,and the OS time of patients in primary EMD group is shorter than that in recurrent EMD group. Bortezomib-based chemotherapy could not improve the prognosis of patients with primary EMD and recurrent EMD, and the prognosis of patients with primary EMD is even worse.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Proportional Hazards Models
/
Retrospective Studies
/
Disease-Free Survival
/
Bortezomib
/
Multiple Myeloma
Type of study:
Observational study
/
Prognostic study
/
Risk factors
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS